ML
Martin A. Lehr
Chief Executive OfficerDirector

Martin A. Lehr insider trades: Context Therapeutics (CNTX) stock purchases

Chief Executive Officer, Context Therapeutics Last trade Jun 9, 2025 16 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
11
Open-market trades
since 2021
1
Company
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Martin reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jun 9, 2025CNTX↑ Buy$70K
Feb 21, 2023CNTX↑ Buy$5K
Feb 13, 2023CNTX↑ Buy$5K
Feb 6, 2023CNTX↑ Buy$5K
Jan 30, 2023CNTX↑ Buy$5K
Jan 23, 2023CNTX↑ Buy$5K
Jan 17, 2023CNTX↑ Buy$5K
Dec 16, 2022CNTX↑ Buy$15K
Aug 19, 2022CNTX↑ Buy$24K
Dec 16, 2021CNTX↑ Buy$42K
Oct 22, 2021CNTX↑ Buy$50K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Martin A. Lehr's insider trades

Martin A. Lehr is Chief Executive Officer at Context Therapeutics (CNTX). Since Oct 22, 2021, Martin has reported 11 open-market purchases worth $230K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (5 filings), other transactions (1 filing), conversions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CNTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.